Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status;Prévalence de l'élévation du CA 15-3 lors de la rechute métastatique des cancers du sein: Corrélation avec l'expression des récepteurs hormonaux et de Her2

Bulletin du Cancer

Volumn 96, Issue 10, 2009, Pages 923-928

  Bensouda, Y ^a,b   Andre F ^a   Boulet, T ^a   Al Ghuzlan, A ^a   Conforti, R ^a   Troalen, F ^a   Bourgier, C ^a   Errihani, H ^b   Spielmann, M ^a   Delaloge, S ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

Author keywords

Breast cancer; CA 15 3; Estrogen receptor; Metastases; Serum marker

Indexed keywords

CA 15-3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; DNA BINDING PROTEIN; ERBB2 PROTEIN, HUMAN; MUCIN 1; NUCLEAR RECEPTOR NUR77; STEROID RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RELAPSE; CANCER SIZE; DISTANT METASTASIS; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; BLOOD; BONE TUMOR; BRAIN TUMOR; BREAST TUMOR; CHEMISTRY; LIVER TUMOR; LUNG CARCINOMA; LUNG TUMOR; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; RETROSPECTIVE STUDY; SKIN TUMOR; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DNA-BINDING PROTEINS; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUCIN-1; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, STEROID; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 70350516298     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0919     Document Type: Article

References (33)

1. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007 ; 25 : 5287-5312
2. Hayes DF. Follow-up of patients with early breast cancer. N Engl J Med 2007 ; 356 : 2505-2513 (Pubitemid 46919776)
3. Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006 ; 24 : 5091-5097
4. European Society of Medical Oncology, ESMO. Minimal clinical recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Ann Oncol 2005 ; 16 (Suppl 1) : 17-19
5. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001 ; 19 : 1865-1878 (Pubitemid 32230890)
6. Soletormos G, Nielsen D, Shioler V, Skovsgaard T, Winkel P, Mouridsen HT, et al. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15-3 compared to CEA and TPA. Ann Oncol 1993 ; 4 : 861-869 (Pubitemid 24032094)
7. Bombardieri E, Pizzichetta M, Veronesi P, Seregni E, Bogni A, Maffioli L, et al. CA 15-3 determination in patients with breast cancer: clinical utility for the detection of distant metastasis. Eur J Cancer 1993 ; 29A : 144-146
8. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, et al. Use of serial carcinoembryonic antigen and Ca 15-3. Assays in detecting relapses in breast cancer patients. Br Cancer Res Treat 1995 ; 36 : 41-48
9. Nicolini A, Carpi A. Postoperative follow-up of breast cancer patients: overview and progress in the use of tumor markers. Tumor Biol 2000 ; 21 : 235-248 (Pubitemid 30435489)
10. Kokko R, Holli K, Hakama M. CA 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer 2002 ; 38 : 1189-1193 (Pubitemid 34603478)
11. Valenzuela P, Mateos S, Tello E, López-Bueno MJ, Garrido N, Gaspar MJ. The contribution of the CEA marker to CA 15-3 in the follow-up of breast cancer. Eur J Gynaecol Oncol 2003 ; 24 : 60-62 (Pubitemid 36268189)
12. Nicolini A, Tartarelli G, Carpi A, Metelli MR, Ferrari P, Anselmi L, et al. Intensive postoperative follow-up of breast cancer patients with tumor markers: CEA, TPA or CA 15-3 vs MCA and MCA-CA 15-3 vs CEA-TPA-CA 15-3 panel in the early detection of distant metastases. BMC Cancer 2006 ; 6 : 269.
13. Duffy JM. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 2006 ; 52 : 345-351
14. Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I, et al. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res 2007 ; 27 : 1963-1968 (Pubitemid 46954709)
15. Surveyor GA, Gendler SJ, Pemberton L, Das SK, Chakraborty I, Julian J, et al. Expression and steroid hormonal control of Muc-1 in the mouse uterus. Endocrinology 1995 ; 136 : 3639-3647
16. McGuckin MA, Quin RJ, Ward BG. Progesterone stimulates production and secretion of MUC1 epithelial mucin in steroid responsive breast cancer cell lines. Int J Oncol 1998 ; 12 : 939-945 (Pubitemid 28133591)
17. Seregni E, Botti C, Bajetta E, Ferrari L, Martinetti A, Nerini-Molteni S, et al. Hormonal regulation of MUC1 expression. Int J Biol Markers 1999 ; 14 : 29-35.
18. Meseguer M, Aplin JD, Caballero-Campo P, O'Connor JE, Martin JC, Remohi J, et al. Human endometrial mucin MUC1 is upregulated by progesterone and down-regulated in vitro by the human blastocyst. Biol Reprod 2001 ; 64 : 590-601. (Pubitemid 32109748)
19. Martín A, Corte MD, Alvarez AM, Rodriguez JC, Andicoechea A, Bongera M, et al. Prognostic value of preoperative serum CA 15-3 levels in breast cancer. Anticancer Res 2006 ; 26 : 3965-3971 (Pubitemid 44701484)
20. Kumpulainen EJ, Keskikuru RJ, Johansson RT. Serum tumor marker CA 15-3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat 2002 ; 76 : 95-102.
21. Park BW, Oh JW, Kim JH, Park SH, Kim KS, Kim JH, et al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 2008 ; 19 : 675-681
22. Gion M, Peloso L, Mione R, Vignati G, Fortunato A, Saracchini S, et al. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients. Cancer J 2001 ; 7 : 181-190 (Pubitemid 33759104)
23. Collazos J, Genolla J, Ruibal A. Breast cancer-associated antigen CA 15-3 in liver cirrhosis. Acta Oncol 1992 ; 31 : 741-744 (Pubitemid 23050609)
24. Colomer CR, Ruibal A, Genolla J, Rubio D, Del Campo JM, Bodi R, et al. Circulating CA 15-3 levels in the postsurgical follow-up breast cancer patients and in non-malignant disease. Breast Cancer Res Treat 1989 ; 13 : 123-133 (Pubitemid 19120104)
25. Hashimoto T, Matsubara F. Changes in the tumor marker concentration in female patients with hyper-, eu-, and hypothyroidism. Endocrinol Jpn 1989 ; 36 : 873-879 (Pubitemid 20174892)
26. Aguiar-Bujanda D, Bohn-Sarmiento U, Morales J. False elevation of serum CA 15-3 levels in patients under follow-up for breast cancer. Breast J 2004 ; 10 : 375-376 (Pubitemid 38924482)
27. Symeonidis A, Kouraklis-Symeonidis A, Apostolopoulos D, Arvanitopoulou E, Giannakoulas N, Vassilakos N, et al. Increased serum CA 15-3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency. Oncology 2004 ; 67 : 359-367
28. Wojtacki J, Kruszewski WJ, Sliwiska M, Kruszewska E, Hajdukiewicz W, Sliwiski W, et al. Elevation of serum CA 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases. Przegl Lek 2001 ; 58 : 498-503.
29. Molina R, Jo J, Filella X, Zanón G, Farrus B, Muñoz M, et al. CerbB-2, CEA and CA 15-3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res 1999 ; 19 : 2551-2555
30. Basuyau JP, Blanc-Vincent MP, Bidart JM, Daver A, Deneux L, Eche N, et al. FLCC, Opération Standards, Options, Recommandations (SOR) : marqueurs tumoraux sériques du cancer du sein. Bull Cancer 2000 ; 87 : 723-737 (Pubitemid 30943463)
31. Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y, et al. Elevated serum CA 15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer. Breast Cancer 2003 ; 10 : 220-227
32. Zaretsky JZ, Barnea I, Aylon Y, Gorivodsky M, Wreschner DH, Keydar I, et al. MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERα) in regulation of the MUC1 gene expression. Mol Cancer 2006 ; 5 : 57. (Pubitemid 44803714)
33. Wei X, Xu H, Kufe D. MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell 2006 ; 21 : 295-305. (Pubitemid 43099944)